Search

Displaying results 4751 - 4760 of 4822 in total
  1. Drug

    Ohmefentanyl

    go.drugbank.com/drugs/DB01570
    ExperimentalIllicit

    Ohmefentanyl has three stereogenic centers and hence, it can derive into eight stereoisomers, currently named F9201–F9208.

  2. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  3. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy.

  4. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  5. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique ...

  6. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). Similar in mechanism to omalizumab, another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its pee...

  7. Drug

    MM-093

    go.drugbank.com/drugs/DB05512
    Investigational

    Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy.

  8. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].

  9. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L10169] It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules.

  10. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs [L1191